Pancreatic Cancer Research

ResearcherFirst Hospital of Lanzhou UniversityActive in the last 2 years

Lihong He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2694-2974; OpenAlex author ID A5026242985. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 12

  1. Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer. Co-author DOI 10.1186/s40164-026-00818-9↗
  2. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Co-author DOI 10.1002/cac2.70038↗
  3. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63146-2↗
  4. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  5. Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2024.101731↗
  6. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Co-author DOI 10.1038/s41420-024-01862-2↗
  7. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Co-author DOI 10.1080/15548627.2023.2300913↗
  8. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021↗
  9. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Co-author DOI 10.1038/s41388-023-02711-9↗
  10. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Co-author DOI 10.1038/s41418-022-01102-z↗
  11. Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer. Co-author DOI 10.3390/cancers15082225↗
  12. The Role and Mechanism of Autophagy in Pancreatic Cancer: An Update Review. Co-author DOI 10.2147/cmar.s328786↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Bai · 10 shared papers, 2023–2026 · strength 1.86
  2. Tingbo Liang · 9 shared papers, 2023–2026 · strength 1.63
  3. Kang Sun · 9 shared papers, 2023–2025 · strength 1.62
  4. Hanshen Yang · 9 shared papers, 2023–2025 · strength 1.58
  5. Xiaozhen Zhang · 8 shared papers, 2023–2026 · strength 1.52
  6. Mengyi Lao · 7 shared papers, 2023–2025 · strength 1.24
  7. Lingyue Liu · 3 shared papers, 2025–2026 · strength 0.64
  8. Jian Xu · 3 shared papers, 2023–2024 · strength 0.49
  9. Tingbo Liang · 2 shared papers, 2024–2025 · strength 0.46
  10. Qingbo Meng · 2 shared papers, 2024 · strength 0.41
  11. Xiongbin Lu · 2 shared papers, 2025 · strength 0.36
  12. Yan Chen · 2 shared papers, 2023–2025 · strength 0.34
  13. Yi Duan · 2 shared papers, 2023 · strength 0.32
  14. Daqian Xu · 1 shared paper, 2025 · strength 0.22
  15. Junming Huang · 1 shared paper, 2025 · strength 0.19
  16. Xinyuan Liu · 1 shared paper, 2025 · strength 0.19
  17. Xiao Zhi · 1 shared paper, 2025 · strength 0.17
  18. Xiang Li Ma · 1 shared paper, 2025 · strength 0.17
  19. Mao Ye · 1 shared paper, 2025 · strength 0.17
  20. Jinyuan Song · 1 shared paper, 2025 · strength 0.17
  21. Xun Li · 1 shared paper, 2021 · strength 0.15
  22. Jian Ma · 1 shared paper, 2021 · strength 0.15
  23. Lei Zhang · 1 shared paper, 2021 · strength 0.15
  24. Zhengtao Hong · 1 shared paper, 2023 · strength 0.14
  25. Yifan Hong · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.